SLS [NASD]
SELLAS Life Sciences Group, Inc.
Index- P/E- EPS (ttm)-2.22 Insider Own1.20% Shs Outstand15.90M Perf Week1.92%
Market Cap67.92M Forward P/E- EPS next Y-1.37 Insider Trans-1.23% Shs Float15.71M Perf Month7.80%
Income-35.00M PEG- EPS next Q-0.38 Inst Own11.40% Short Float6.00% Perf Quarter-46.10%
Sales2.90M P/S23.42 EPS this Y36.60% Inst Trans-1.81% Short Ratio3.33 Perf Half Y-53.37%
Book/sh0.25 P/B12.72 EPS next Y-2.00% ROA-108.40% Target Price12.25 Perf Year-68.95%
Cash/sh0.67 P/C4.75 EPS next 5Y- ROE-166.10% 52W Range2.10 - 15.08 Perf YTD-42.50%
Dividend- P/FCF- EPS past 5Y73.00% ROI-123.40% 52W High-78.91% Beta1.50
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin93.10% 52W Low51.43% ATR0.30
Employees11 Current Ratio1.70 Sales Q/Q-82.50% Oper. Margin- RSI (14)49.45 Volatility12.91% 10.99%
OptionableYes Debt/Eq0.00 EPS Q/Q-552.10% Profit Margin- Rel Volume0.37 Prev Close3.10
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume282.61K Price3.18
Recom1.70 SMA2012.74% SMA50-21.99% SMA200-51.70% Volume105,432 Change2.58%
Jul-21-21Initiated Cantor Fitzgerald Overweight $18
Nov-01-18Initiated Oppenheimer Outperform
Apr-02-18Initiated H.C. Wainwright Buy $11
Mar-19-18Upgrade Maxim Group Hold → Buy $13
May-12-22 04:12PM  
Apr-26-22 08:30AM  
Apr-11-22 08:15AM  
07:30AM  
Apr-06-22 07:00AM  
Apr-05-22 04:51PM  
Apr-04-22 07:00AM  
Apr-01-22 08:41AM  
Mar-31-22 09:03PM  
04:11PM  
04:08PM  
Mar-21-22 05:51PM  
07:00AM  
Mar-14-22 07:00AM  
Feb-28-22 09:00AM  
Feb-01-22 08:30AM  
Jan-26-22 08:00PM  
Jan-05-22 08:30AM  
Dec-21-21 08:34AM  
Nov-23-21 08:30AM  
Nov-12-21 08:45AM  
Oct-07-21 09:14AM  
Sep-23-21 04:05PM  
Sep-22-21 10:28AM  
Sep-14-21 08:30AM  
Aug-12-21 04:22PM  
Jul-28-21 08:30AM  
Jun-30-21 08:55AM  
Jun-24-21 08:30AM  
06:45AM  
Jun-22-21 09:05AM  
Jun-18-21 03:23PM  
May-27-21 08:30AM  
May-13-21 04:25PM  
May-11-21 07:30AM  
Mar-25-21 06:04AM  
Mar-23-21 04:21PM  
Mar-11-21 08:30AM  
Jan-14-21 08:30AM  
Dec-21-20 08:30AM  
Dec-17-20 08:30AM  
Dec-13-20 08:10PM  
Dec-11-20 08:30AM  
Dec-10-20 04:12PM  
Dec-07-20 08:30AM  
Nov-13-20 04:32PM  
Nov-09-20 09:30AM  
Sep-09-20 08:30AM  
Aug-13-20 04:30PM  
Jul-31-20 01:30PM  
Jul-08-20 07:51PM  
Jun-23-20 08:12AM  
Jun-11-20 08:30AM  
Jun-03-20 09:00AM  
May-22-20 08:30AM  
May-18-20 08:30AM  
May-14-20 04:33PM  
May-07-20 08:00AM  
Apr-28-20 08:30AM  
Apr-16-20 08:30AM  
Mar-18-20 08:30AM  
Mar-13-20 08:30AM  
Mar-10-20 12:03PM  
Feb-26-20 08:30AM  
Feb-14-20 08:30AM  
Feb-11-20 08:30AM  
Feb-10-20 08:45AM  
Jan-13-20 08:30AM  
Jan-10-20 07:13AM  
Jan-09-20 09:00AM  
Jan-08-20 08:30AM  
Jan-06-20 08:15AM  
Dec-04-19 08:00AM  
Nov-19-19 01:28PM  
Nov-14-19 04:30PM  
Nov-08-19 08:00AM  
Nov-06-19 09:20AM  
Aug-14-19 04:15PM  
Aug-05-19 08:30AM  
Jul-31-19 08:15AM  
Jun-22-19 10:10AM  
Jun-18-19 04:33PM  
Jun-14-19 08:30AM  
Jun-03-19 08:30AM  
May-17-19 08:03AM  
May-15-19 04:30PM  
Apr-04-19 08:30AM  
Mar-22-19 08:39AM  
Mar-04-19 08:30AM  
Feb-26-19 10:49AM  
08:30AM  
Feb-12-19 08:45AM  
Jan-31-19 08:30AM  
Jan-08-19 08:30AM  
Dec-06-18 08:30AM  
Nov-30-18 08:30AM  
Nov-28-18 08:30AM  
Nov-26-18 08:30AM  
Nov-15-18 07:30AM  
Nov-12-18 07:00AM  
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stergiou Angelos M.President and CEODec 02Sale6.252,12013,252121,167Dec 03 05:15 PM
Burns John ThomasVP, Finance & Corp ControllerDec 02Sale6.272311,44817,644Dec 03 05:13 PM
WOOD BARBARA AEVP, Gen. Counsel, Corp. Sec.Dec 02Sale6.258475,29842,028Dec 03 05:14 PM